Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

Cerecor Inc. (CERC), a clinical stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into a $15 million common stock purchase agreement (the “Agreement”) and a registration
rights agreement with Aspire Capital Fund, LLC (“Aspire”), a Chicago based institutional investor.

This entry was posted in Recent Development News: Q3 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »